Readmission following methotrexate treatment for tubal pregnancy
International Journal of Gynecology & Obstetrics · 2024
DOI: 10.1002/ijgo.15498 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2024. Verfasst von Yossi Bart und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel. Hauptthemen laut MEDLINE: Methotrexate, Patient Readmission, Pregnancy, Tubal, Abortifacient Agents, Nonsteroidal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objective
To identify risk factors for readmission following methotrexate treatment for tubal pregnancy.
Methods
A retrospective study undertaken in two tertiary medical centers, including all individuals with medically treated tubal pregnancy ( N = 511), between December 2009 and June 2021. Individuals with and without readmission following methotrexate treatment were compared. The primary outcome was the readmission rate. Secondary outcomes included the rate of post‐discharge gynecological emergency department visits, tubal rupture rate, and the eventual need for surgical treatment.
Results
Readmission following methotrexate treatment occurred in 224/511 patients (43.8%). Most readmissions were due to abdominal pain or suspicion of treatment failure. Readmitted individuals were more likely to have a history of pelvic inflammatory disease and pretreatment serum human chorionic gonadotropin (hCG) >2000 mIU/mL. Both factors remained significantly associated with higher readmission rates in a logistic regression analysis (adjusted odds ratio [OR] 6.28, 95% confidence interval [CI] 1.30–30.45, and adjusted OR 2.73, 95% CI 1.83–4.07, respectively) after adjustment for age, endometriosis, tubal pathology, abdominal pain, and presence of yolk sac or embryo at diagnosis. A dose‐dependent association was observed between pretreatment serum hCG levels and readmission rate ( P < 0.001). Pretreatment hCG levels were also associated with tubal rupture and the eventual need for surgical treatment ( P < 0.001 for both). A prediction model using hCG was not sufficiently accurate to predict readmission risk.
Conclusion
Readmission following methotrexate treatment for tubal pregnancy was independently associated with previous pelvic inflammatory disease and pretreatment serum hCG levels. The latter was also associated with surgical intervention rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.
- Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
- Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.
- Department of Obstetrics and Gynecology, Bnai Zion Medical Center, Haifa, Israel.
ORCID-Profile: Yossi Bart
Zitieren
APA
Bart, Y., Regev, N., Shani, U., Cohen, B., Yossef, F., Margieh, N., & Kugelman, N. (2024). Readmission following methotrexate treatment for tubal pregnancy. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.15498
Vancouver
Bart Y, Regev N, Shani U, Cohen B, Yossef F, Margieh N, et al. Readmission following methotrexate treatment for tubal pregnancy. International Journal of Gynecology & Obstetrics. 2024. doi:10.1002/ijgo.15498
BibTeX
@article{Bart2024,
author = {Bart, Yossi and Regev, Noam and Shani, Uria and Cohen, Bracha and Yossef, Fayrooz and Margieh, Nadine and Kugelman, Nir},
title = {Readmission following methotrexate treatment for tubal pregnancy},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
doi = {10.1002/ijgo.15498}
}
EUVIMED